By Chris Wack
Roivant Sciences said its subsidiary Kinevant Sciences' phase 2 study of Namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis.
The phase 2 study showed that Namilumab failed to meet the primary endpoint of proportion of subjects with a rescue event during the double-blind period. Rescue event was defined as clinically significant worsening of a subject's disease requiring treatment, failure to adhere to protocol, or premature discontinuation from the study associated with lack of benefit during the double-blind treatment period.
Pulmonary sarcoidosis is a lung disease characterized by the presence of clumps of immune cells that can cause breathlessness, fatigue and pain.
The study's secondary goals, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient reported King's Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint.
The safety profile of namilumab in the study was similar to previous studies.
Kinevant will be discontinuing further development of namilumab for the treatment of sarcoidosis, and it will publish the results to inform future sarcoidosis research.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 07:35 ET (12:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.